Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 8 · below the Ichimoku cloud · RSI 37 · MACD below its signal · 2% above its 52-week low
None of the 29 investors followed here reported a position in EOCN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a EOCN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for EOCN.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.5 | -13.8 | -19.9 | 16.3 | 32.3 | -26.3 | 11.7 | -17.1 | -15.3 | -9.3 | −47.3% | ||
| 2025 | -12.9 | -23.0 | -32.7 | -9.7 | 10.0 | 28.7 | -11.4 | -22.1 | 8.7 | -0.7 | -31.4 | -20.1 | −76.5% |
| 2024 | -17.6 | 5.6 | -12.6 | 1.7 | 5.1 | -25.7 | 11.6 | -8.3 | 103.0 | -51.3 | -14.4 | 11.5 | −41.6% |
| 2023 | 32.2 | -27.4 | -11.0 | -27.4 | -0.9 | -35.1 | -61.5 | -29.6 | -23.5 | -38.7 | -6.6 | 28.2 | −93.9% |
| 2022 | -11.0 | -11.1 | 10.4 | 4.4 | -69.2 | 27.0 | -22.8 | -7.6 | -33.0 | 22.2 | -23.2 | 71.2 | −72.5% |
| 2021 | 19.0 | 7.3 | -13.6 | -5.0 | -20.2 | 16.9 | -18.1 | 31.3 | -14.7 | -11.5 | 2.0 | -27.8 | −41.5% |
| 2020 | -10.4 | -6.4 | -28.7 | 26.0 | 8.9 | 0.6 | 1.5 | 0.6 | -27.7 | -11.9 | 23.8 | -19.2 | −46.2% |
| 2019 | 15.8 | 4.2 | -0.8 | -4.9 | -22.7 | 22.3 | -17.8 | -13.7 | -8.3 | -12.4 | 7.5 | 28.4 | −15.4% |
| 2018 | 9.1 | -48.7 | 8.8 | 6.6 | 6.2 | 88.6 | 14.1 | -0.2 | 0.2 | -34.1 | -4.2 | -20.3 | −25.4% |
| 2017 | 16.2 | 27.4 | -5.9 | 5.9 | -2.5 | 22.8 | 13.7 | 15.0 | 12.7 | -10.3 | -2.0 | 13.8 | +160.7% |
| 2016 | -17.9 | -26.2 | 6.9 | 26.8 | -33.0 | 7.2 | -4.9 | -9.8 | 15.3 | -23.4 | 3.2 | 0.0 | −53.9% |
| 2015 | 12.4 | 45.6 | -0.7 | -11.4 | 26.6 | -4.8 | 0.7 | -11.5 | -17.2 | 29.5 | -2.4 | -19.0 | +31.2% |
| 2014 | -29.8 | -16.3 | 44.5 | -18.7 | -13.9 | 26.1 | -23.0 | -10.9 | -1.7 | −49.4% |
No analyst coverage for this instrument.
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.